ERS Genomics Enters into a Licensing Deal with Japan SLC for CRISPR/Cas9 Patent Portfolio
shot by IP News Shots / 6:08 pm on 29 July, 2021
ERS Genomics Limited and Japan SLC have entered a patent licensing agreement. The agreement will provide non-exclusive access to Japan SLC to the CRISPR/Cas9 patent portfolio belonging to ERS Genomics.
Industry: Biotechnology
Read more at Technology Networks
Bio-Rad and 10x Genomics Reach Cross-Licensing Settlement, End Patent Disputes
shot by IP News Shots / 6:57 pm on 28 July, 2021
Bio-Rad Laboratories, Inc. and 10x Genomics, Inc. have settled patent disputes spanning across countries and even at the US International Trade Commission (ITC). The settlement includes a global patent cross-licensing agreement. As per the terms of the agreement, the two companies will have non-exclusive, royalty bearing and worldwide license to each other’s patents relating to single-cell genomics.
Industry: Biotechnology
Read more at Business Wire
WHO Committee’s Views on Distribution of Genome Editing Patents
shot by IP News Shots / 6:28 pm on 15 July, 2021
The World Health Organization (WHO) committee has urged genome editing patents holders to strive to maintain equitable distribution of the technology across the world. The committee went on to say that a group should be put together with a representative from among the various stakeholders to work on the ethical licensing of the relevant patents.
Industry: Biotechnology
Read more at Law360
Nippon Shinyaku Alleges Patent Infringement by Sarepta, Seeks Injunction over its Patent Review Petitions
shot by IP News Shots / 6:03 pm on 14 July, 2021
A patent infringement complaint has been filed by Nippon Shinyaku Co., Ltd. at the US District Court for the District of Delaware. Along with the infringement allegation, Nippon Shinyaku also seeks to block inter partes review petitions filed by the defendant Sarepta Therapeutics, Inc. at the Patent Trial and Appeal Board (PTAB). Sarepta has challenged seven of Nippon’s patents relating to gene therapy for Duchenne Muscular dystrophy.
Industry: Biotechnology
Read more at Bloomberg Law
10x Seeks Reversal of Patent Infringement Verdict in Bio-Rad Case Under the Assignor Estoppel Ruling by SCOTUS
shot by IP News Shots / 6:01 pm on 14 July, 2021
10x Genomics, Inc. has approached the US Court of Appeals for the Federal Circuit (CAFC) urging it to review an earlier ruling by the court which upheld the US International Trade Commission’s (ITC’s) decision favouring Bio-Rad Laboratories Inc. 10x was found guilty of infringing on Bio-Rad’s patents for gene sequencing chips but the former challenged the patents, which was refused by the commission. In its present appeal, 10x is using the assignor estoppel ruling by the Supreme Court of the US (SCOTUS) in hope of challenging the Bio-Rad patents.
Industry: Biotechnology, Healthcare Technology
Read more at Law360
Delaware Chancery Court Judge Narrows Scope in Patent Dispute between Humanigen and Savant
shot by IP News Shots / 6:24 pm on 13 July, 2021
The Delaware Court of Chancery gave several rulings in the summary judgement motions presented by opposing parties in a patent dispute. The judge narrowed down the scope of the patent case between Humanigen Inc. and Savant Neglected Diseases LLC.
Industry: Biotechnology, Pharmaceuticals
Read more at Law360